[KoNECT] 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 1.22.(월)

​

구분	보고서 (영문)
제약/바이오/ 임상시험	Major Depressive Disorder Market to Reach $9.6 Billion Across 8MM by 2029
	Clinical Trials: What to Expect in 2024 – a Preview of Trials Planned to Initiate and Estimated to Complete
	Female Contraceptives Market Is Still in Need of Therapeutics with Better Safety Profiles
	Eli Lilly and Innovent’s Obesity Drug Mazdutide Achieves Positive Phase III Results
	AbbVie’s Produodopa Holds Potential to Become the First-Choice Pump for Advanced Parkinson’s
	Zosurabalpin Shows Promise in the Fight Against Antibacterial Resistance
	XORTX Therapeutics Looking to Enter CKD Space with Lead Product XRX-008
	EU Access to Oncology Medicines Lags Behind in the Netherlands
질환별	Acute Ischemic Stroke: Competitive Landscape
	Hyperinsulinemia: Competitive Landscape
	ADHD Unmet Needs Present Opportunities for the Development of New Non-stimulants
	Brazilian Study Explores Tuberculosis Risk Among Household Contacts
	Obesity Disease Management Needs to Be Revolutionized
	Revolutionizing Lung Health: the Promise of PATROL for Early Detection
	ECDC Report Suggests Respiratory Infections Could Surge This Winter
	Vaccine Hesitancy Causes Cases of Measles to Rise in the UK
	Major Depressive Disorder: 68-Market Analysis and Sales Forecast
	Urgent Call for Earlier Diagnosis to Improve Gaucher Disease Patient Outcomes
컨퍼런스/ 심포지엄/ 학회/기타	Global Risk Report (Quarterly Update) Q3 2023
	Amgen Showcases Exciting Potential in the Obesity Space at JPM24